B12 and folate deficiency in the UK: why it is missed and how to read the tests
B12 and folate deficiency get missed because the symptoms are vague, the first-line blood test is imperfect, and a normal full blood count does not rule it out. Serum B12 measures mostly inactive vitamin, so it can read “normal” while the tissue-available fraction is low. The honest approach is to read serum B12 against active B12 (holotranscobalamin) or methylmalonic acid when the result is borderline, to always check folate and B12 together, and to never correct folate before B12 has been excluded.
Key facts
- NICE (2024) treats a serum B12 below 180 nanograms per litre (133 pmol/L) as confirmed deficiency, and 180 to 350 as an indeterminate result that may need a follow-up methylmalonic acid (MMA) test.1
- A normal full blood count does not exclude deficiency: NICE explicitly says do not rule out B12 deficiency on the absence of anaemia or large red cells (macrocytosis) alone.1
- Giving folic acid to someone who is actually B12 deficient can correct the anaemia while the neurological damage quietly continues, which is why folate and B12 are read together.2
- Long-term metformin and proton pump inhibitors both raise risk: in the Diabetes Prevention Program, risk rose about 13 percent per year of metformin use, and two or more years of PPIs carried an odds ratio of 1.65 for B12 deficiency.34
Why it gets missed
The classic teaching links B12 deficiency to a particular kind of anaemia, with enlarged red cells. That picture is real but late, and it traps clinicians and patients alike. Neurological injury can begin before the blood count budges, so waiting for anaemia means waiting for harm. NICE is blunt about this: a diagnosis should not be ruled out on the absence of anaemia or macrocytosis alone.1
The symptoms themselves are unhelpfully generic. Fatigue, pins and needles or numbness (paraesthesia), unsteadiness, a sore smooth tongue (glossitis), low mood, anxiety and difficulty concentrating (often described as brain fog) all overlap with dozens of other conditions. NICE lists cognitive difficulty, mood disturbance, optic-nerve eyesight problems, glossitis and peripheral neuropathy among the common signs, and notes that B12 deficiency can present as depression, anxiety or even psychosis.1 The advanced neurological form, subacute combined degeneration of the spinal cord, damages the columns that carry position sense, producing balance problems and falls.2
So the deficiency is missed twice: once because the symptoms are dismissed as stress or ageing, and again because the standard test is read as reassuring when it is not.
Why serum B12 is an imperfect test
Total serum B12 (serum cobalamin) measures all the B12 circulating in your blood. The problem is that most of it is bound to a protein called haptocorrin and is biologically unavailable. Only the fraction bound to transcobalamin, called holotranscobalamin or active B12, can actually be delivered into cells. Because the inactive pool dominates the measurement, total B12 can sit in the normal range while the active fraction, and therefore the supply to your tissues, is already low.
This is why a single B12 number is a screening tool, not a verdict. NICE now allows either total B12 or active B12 as the initial test, and recommends active B12 first in pregnancy.1 Active B12 falls earlier than total B12 as stores deplete, and head-to-head studies report higher diagnostic accuracy for holotranscobalamin than for total B12, although reported sensitivity and specificity vary by population and cut-off.5
Evidence note: active B12 is a better marker than total B12, but it is not perfect either. Both are early indicators of supply; MMA reflects whether cells are actually short of B12 at the metabolic level. No single blood test is definitive, which is why borderline results are resolved with a second, different marker rather than repeated guesses.
How to read the tests when the result is borderline
The useful concept is a ladder of markers. Total or active B12 estimates supply. When B12 runs low inside the cell, a substrate called methylmalonyl-CoA cannot be processed, so methylmalonic acid (MMA) accumulates and rises in the blood. Homocysteine also rises, but it is less specific because it climbs in folate deficiency too. NICE recommends considering a serum MMA test when someone has symptoms but an indeterminate B12 result.1
| Marker | What it reflects | How to interpret |
|---|---|---|
| Total B12 (serum cobalamin) | All circulating B12, mostly inactive | Below 180 ng/L confirms deficiency; 180 to 350 is indeterminate; above 350 makes deficiency unlikely.1 |
| Active B12 (holotranscobalamin) | The fraction available to cells | Below 25 pmol/L confirms deficiency; 25 to 70 is indeterminate; above 70 makes it unlikely. First-line in pregnancy.1 |
| Methylmalonic acid (MMA) | Cellular B12 sufficiency | Raised supports true deficiency, but is also lifted by kidney impairment and dehydration, so interpret with care.16 |
| Homocysteine | B12 and folate status | Raised in B12 or folate deficiency; not specific, and folate deficiency must be taken into account.1 |
One important caveat: MMA is not a magic confirmatory test. It rises in reduced kidney function and dehydration, so a high MMA with normal kidneys strengthens the case for deficiency, whereas a high MMA with impaired renal function is harder to read.6 This pattern-reading, holding several numbers against each other rather than trusting one, is the same skill that turns confusing results into answers across our health library.
The folate trap
B12 and folate work together in the same methylation cycle, and both deficiencies cause the same large-cell anaemia. Here is the danger. If a person is genuinely B12 deficient and is given folic acid, the folate can push red-cell production back to normal and tidy up the blood count. The anaemia, the thing that would have prompted investigation, disappears. But folate does nothing for the B12-dependent maintenance of the spinal cord and nerves, so the neurological damage carries on unseen.2
This is not a theoretical worry. It is exactly why the NHS advises checking B12 before starting folic acid for folate deficiency, because treating folate can mask an underlying B12 problem and let it harm the nervous system.7 The rule is simple: test folate and B12 together, and treat B12 first, or alongside, never folate alone.
Safety: if you have neurological symptoms (numbness, tingling, balance problems) alongside fatigue, do not self-treat with high-dose folic acid or a B-complex before B12 has been measured and addressed. Folate can blunt the anaemia and delay the diagnosis that protects your nerves.
Who is at risk
NICE recommends testing people who have at least one symptom and at least one risk factor.1 The main groups are worth knowing.
- Vegans and strict vegetarians. B12 comes almost entirely from animal foods. Without reliable fortified foods or supplements, deficiency is common; UK data have reported deficiency in around half of male vegans in one sample, with wide variation by cut-off and supplement use.8
- People on metformin. Long-term use lowers B12 absorption. In the Diabetes Prevention Program Outcomes Study, risk rose roughly 13 percent for each year of use, and the MHRA now advises monitoring B12 in at-risk patients.3
- People on long-term acid suppression. Proton pump inhibitors and H2 blockers reduce the stomach acid needed to free B12 from food. Two or more years of PPI use carried an odds ratio of 1.65 in a large Kaiser Permanente case-control study of nearly 26,000 cases.4
- Older adults. Reduced stomach acid, lower intake and more medicines combine to make deficiency common with age.1
- Autoimmune gastritis (the cause of classic pernicious anaemia). Antibodies attack the stomach cells that make intrinsic factor, the carrier B12 needs to be absorbed. NICE suggests an anti-intrinsic factor antibody test when this is suspected, while noting a negative result does not exclude it.1
If you are mapping several risk factors or medicines at once, our stack builder can help you lay out what you are taking and where the gaps are.
UK testing and treatment
Treatment depends on cause. Where the problem is absorption, such as autoimmune gastritis or surgery that removed part of the stomach or small bowel, treatment is hydroxocobalamin by intramuscular injection, and it is lifelong.1 The UK uses hydroxocobalamin rather than cyanocobalamin because it stays in the body longer.7
The standard NHS loading regimen is hydroxocobalamin 1 mg on alternate days for two weeks, or until symptoms stop improving where there is neurological involvement, followed by maintenance every two to three months (every two months if there were neurological symptoms).7 Where the cause is purely dietary, NICE supports oral B12 replacement, at a dose of at least 1 mg a day, with injections reserved for those who cannot absorb or adhere to tablets.1 Crucially, NICE advises taking blood for diagnosis before starting replacement, but not delaying treatment in anyone with neurological symptoms.1
For background on how reference ranges and functional thresholds differ across blood tests, our insights articles cover the wider principle, and new readers can start with our start page.
What to ask your GP
- My B12 is in range but I have fatigue, numbness, glossitis or low mood: can we check active B12 (holotranscobalamin) or MMA before calling it normal?
- Can we test folate and B12 together, and make sure B12 is covered before I am given folic acid?
- I take metformin, a PPI or follow a vegan diet: should my B12 be monitored as a known risk factor?
- If pernicious anaemia or autoimmune gastritis is possible, can we do an anti-intrinsic factor antibody test, knowing a negative result does not rule it out?
- If I need treatment, would hydroxocobalamin injections or high-dose oral B12 suit my cause, and how will we follow up?
References
- National Institute for Health and Care Excellence. Vitamin B12 deficiency in over 16s: diagnosis and management. NICE guideline NG239, 2024. nice.org.uk.
- Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurology. 2006;5(11):949-960. PMID 17052662.
- Aroda VR, Edelstein SL, Goldberg RB, et al. Long-term metformin use and vitamin B12 deficiency in the Diabetes Prevention Program Outcomes Study. J Clin Endocrinol Metab. 2016;101(4):1754-1761. PMC4880159.
- Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. JAMA. 2013;310(22):2435-2442. jamanetwork.com.
- Nexo E, Hoffmann-Lucke E. Holotranscobalamin, a marker of vitamin B-12 status: analytical aspects and clinical utility. Am J Clin Nutr. 2011;94(1):359S-365S. PMC3127504.
- Vashi P, Edwin P, Popiel B, et al. Methylmalonic acid and homocysteine as indicators of vitamin B-12 deficiency in cancer. PLoS One. 2016;11(1):e0147843. PMC4726582.
- NHS. Vitamin B12 or folate deficiency anaemia: treatment. 2023. nhs.uk.
- Pawlak R, Lester SE, Babatunde T. The prevalence of cobalamin deficiency among vegetarians assessed by serum vitamin B12: a review of literature. Eur J Clin Nutr. 2014;68(5):541-548. PMID 24667752.
This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation. Medication uses described as “off-label” are not licensed for that purpose in the UK and should only be considered under qualified clinical supervision. Always speak to your GP, pharmacist, or a registered specialist before starting, stopping, or changing any treatment. If you have severe or alarm symptoms - unintentional weight loss, blood in your stool, difficulty swallowing, persistent vomiting, a fever, or severe pain - seek urgent medical care.